Nothing Special   »   [go: up one dir, main page]

ATE233813T1 - Veränderte immunglobuline für spezifische fc- epsilon rezeptoren - Google Patents

Veränderte immunglobuline für spezifische fc- epsilon rezeptoren

Info

Publication number
ATE233813T1
ATE233813T1 AT92918713T AT92918713T ATE233813T1 AT E233813 T1 ATE233813 T1 AT E233813T1 AT 92918713 T AT92918713 T AT 92918713T AT 92918713 T AT92918713 T AT 92918713T AT E233813 T1 ATE233813 T1 AT E233813T1
Authority
AT
Austria
Prior art keywords
ige
receptor
immunolobulins
modified
specific
Prior art date
Application number
AT92918713T
Other languages
English (en)
Inventor
Paula M Jardieu
Leonard G Presta
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27114350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE233813(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE233813T1 publication Critical patent/ATE233813T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT92918713T 1991-08-14 1992-08-14 Veränderte immunglobuline für spezifische fc- epsilon rezeptoren ATE233813T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74476891A 1991-08-14 1991-08-14
US87949592A 1992-05-07 1992-05-07
PCT/US1992/006860 WO1993004173A1 (en) 1991-08-14 1992-08-14 Immunoglobulin variants for specific fc epsilon receptors

Publications (1)

Publication Number Publication Date
ATE233813T1 true ATE233813T1 (de) 2003-03-15

Family

ID=27114350

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92918713T ATE233813T1 (de) 1991-08-14 1992-08-14 Veränderte immunglobuline für spezifische fc- epsilon rezeptoren

Country Status (12)

Country Link
EP (2) EP1260521B1 (de)
JP (1) JP3457962B2 (de)
AT (1) ATE233813T1 (de)
AU (2) AU2498192A (de)
CA (1) CA2113813C (de)
DE (3) DE69233716T2 (de)
DK (2) DK0602126T3 (de)
ES (2) ES2193136T3 (de)
HK (2) HK1050696A1 (de)
LU (1) LU91219I2 (de)
NL (1) NL300220I2 (de)
WO (1) WO1993004173A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770396A (en) * 1992-04-16 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
EP1452542A3 (de) * 1992-09-24 2007-05-02 Novartis AG Umgestaltete humane monoklonale Antikörper gegen IgE
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
GB9324013D0 (en) * 1993-11-22 1994-01-12 3I Res Expl Ltd Polypeptides
ATE164079T1 (de) * 1994-01-18 1998-04-15 Genentech Inc Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
BR9707819A (pt) * 1996-03-01 1999-07-27 Novartis Ag Imunogenos peptidicos
US5958880A (en) * 1996-12-19 1999-09-28 Heska Corporation Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6057127A (en) 1998-01-29 2000-05-02 Heska Corporation Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6504013B1 (en) * 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
PL350992A1 (en) * 1999-02-25 2003-02-24 Smithkline Beecham Biolog Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
US6889145B1 (en) 2000-03-15 2005-05-03 Northwestern University Three-dimensional model of a Fc region of an IgE antibody and uses thereof
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
ATE442862T2 (de) 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
JP4460302B2 (ja) 2002-02-05 2010-05-12 ジェネンテック インコーポレイテッド タンパク質精製法
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
BRPI0316092B8 (pt) 2002-11-08 2021-05-25 Ablynx Nv anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
EP2284192A3 (de) 2002-11-08 2011-07-20 Ablynx N.V. Antikörper aus Camelidae zur sublingualen Verabreichung
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
KR101208291B1 (ko) 2003-04-04 2012-12-05 노파르티스 아게 고농도 항체 및 단백질 제형
US7485704B2 (en) 2003-07-28 2009-02-03 Genentech, Inc. Reducing protein A leaching during protein A affinity chromatography
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI320788B (en) 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
US8080249B2 (en) * 2005-06-30 2011-12-20 Risk Glifford G Methods to treating chronic obstructive pulmonary disease
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079302A2 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
BRPI0806367A2 (pt) 2007-01-22 2011-09-06 Genentech Inc métodos de purificação de anticorpos
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2188302B1 (de) 2007-07-09 2017-11-01 Genentech, Inc. Verhinderung der reduktion der disulfidbindung während der rekombinanten herstellung von polypeptiden
PE20120259A1 (es) 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
ES2609280T3 (es) 2007-08-23 2017-04-19 Lsi Medience Corporation Inhibidor de reacción no específica
DK2840090T3 (en) 2007-10-30 2018-04-23 Genentech Inc Antibody purification by cation exchange chromatography
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
RS59232B1 (sr) 2008-08-14 2019-10-31 Genentech Inc Postupci za uklanjanje zagađivača koristeći hromatografiju membrane razmene jona sa razmeštanjem autohtonih proteina
WO2010030670A2 (en) 2008-09-10 2010-03-18 Genentech, Inc. Compositions and methods for the prevention of oxidative degradation of proteins
WO2010074953A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Stirred tank reactor and method
CN102256993A (zh) 2008-12-16 2011-11-23 米利波尔公司 蛋白的纯化
WO2010099273A1 (en) 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
BRPI1006519A2 (pt) 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
IL264336B2 (en) 2009-08-11 2024-02-01 Genentech Inc Production of proteins in cell culture medium without glutamine
CN108409829A (zh) 2009-09-01 2018-08-17 弗·哈夫曼-拉罗切有限公司 通过改进的a蛋白洗脱增强的蛋白质纯化
CA2792125C (en) 2010-03-22 2019-02-12 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
EP2566510A1 (de) 2010-05-03 2013-03-13 F. Hoffmann-La Roche AG Zusammensetzungen und verfahren zur reduzierung der viskosität von proteinhaltigen formulierungen
SG10201804385YA (en) 2010-05-17 2018-06-28 Emd Millipore Corp Stimulus responsive polymers for the purification of biomolecules
EP2576580B1 (de) 2010-05-28 2016-09-14 F.Hoffmann-La Roche Ag Senkung eines lactatspiegels und erhöhung einer polypeptidherstellung durch herunterregulierung der expression von lactatdehydrogenase- und pyruvatdehydrogenase-kinase
CA3111727C (en) 2010-06-24 2022-07-26 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
EP2603525A1 (de) 2010-08-13 2013-06-19 F.Hoffmann-La Roche Ag Antikörper gegen il-1beta und il-18 zur behandlung von krankheiten
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
ES2809211T3 (es) 2011-07-08 2021-03-03 Emd Millipore Corp Filtros de profundidad mejorados para procesos biotecnológicos desechables
WO2013087914A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
MY172426A (en) 2011-12-22 2019-11-25 Genentech Inc Ion exchange membrane chromatography
BR112014023176B1 (pt) 2012-03-27 2021-09-28 Genentech, Inc. Métodos de produção de uma proteína recombinante
EP3427721A1 (de) 2012-05-18 2019-01-16 Genentech, Inc. Hochkonzentrierte monoklonale antikörperformulierungen
GB2503883A (en) * 2012-07-09 2014-01-15 King S College London Variant IgE with reduced affinity to CD23
CN104994885B (zh) 2012-12-19 2017-09-29 基因泰克公司 用于放射性卤素蛋白质标记的方法和组合物
MX2017000231A (es) 2014-07-09 2017-06-27 Genentech Inc Ajuste del ph para mejorar la recuperacion por descongelamiento de bancos de celulas.
SG11201808562SA (en) 2016-03-29 2018-10-30 Geltor Inc Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
AU2017382281B2 (en) 2016-12-22 2024-07-11 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
EP3565587A4 (de) * 2017-01-06 2020-12-16 The Regents of The University of California Therapeutische anti-ige-antikörper und verfahren und zusammensetzungen davon
US12043845B2 (en) 2017-06-08 2024-07-23 Polpharma Biologics S.A. Methods of cell culture
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
EP3708188A4 (de) 2017-11-07 2021-12-01 HuBit genomix, Inc. Verfahren zur hemmung des erwerbs einer allergischen prädisposition in der säuglingsphase durch unterdrückung von ige-klassenspezifischer immunreaktivität
ES2976708T3 (es) 2018-07-03 2024-08-07 Bristol Myers Squibb Co Métodos para producir proteínas recombinantes
CN113166695A (zh) 2018-10-10 2021-07-23 勃林格殷格翰国际公司 用于高密度生物反应器培养中的膜气体转移的方法
CA3133652A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
AU2020270920A1 (en) 2019-04-12 2021-11-04 Geltor, Inc. Recombinant elastin and production thereof
KR20220039777A (ko) 2019-08-01 2022-03-29 브리스톨-마이어스 스큅 컴퍼니 유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
BR112023000400A2 (pt) 2020-07-10 2023-03-21 Shanghai Jemincare Pharmaceutical Co Ltd Anticorpo anti-ige engenheirado e aplicação do mesmo
WO2022066595A1 (en) 2020-09-22 2022-03-31 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
JPS63225397A (ja) * 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
US4940782A (en) * 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
GB8727045D0 (en) * 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
WO1989006138A1 (en) * 1987-12-31 1989-07-13 Tanox Biosystems, Inc. UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES

Also Published As

Publication number Publication date
EP1260521A2 (de) 2002-11-27
AU7038096A (en) 1997-01-16
DK0602126T3 (da) 2003-06-16
NL300220I1 (nl) 2006-04-03
EP0602126B1 (de) 2003-03-05
NL300220I2 (nl) 2006-08-01
HK1014542A1 (en) 1999-09-30
DE69233716D1 (de) 2008-01-03
WO1993004173A1 (en) 1993-03-04
JP3457962B2 (ja) 2003-10-20
DE122006000006I1 (de) 2006-04-27
JPH06509944A (ja) 1994-11-10
AU2498192A (en) 1993-03-16
CA2113813A1 (en) 1993-03-04
AU706584B2 (en) 1999-06-17
ES2193136T3 (es) 2003-11-01
DE122006000006I2 (de) 2011-06-16
DK1260521T3 (da) 2008-03-25
DE69232944D1 (de) 2003-04-10
HK1050696A1 (en) 2003-07-04
ES2296839T3 (es) 2008-05-01
DE69233716T2 (de) 2008-10-30
CA2113813C (en) 2005-04-12
AU706584C (en) 2003-07-10
EP1260521A3 (de) 2004-01-02
EP1260521B1 (de) 2007-11-21
LU91219I2 (fr) 2006-04-03
DE69232944T2 (de) 2003-12-24
EP0602126A1 (de) 1994-06-22

Similar Documents

Publication Publication Date Title
ATE233813T1 (de) Veränderte immunglobuline für spezifische fc- epsilon rezeptoren
DE69841514D1 (de) Menschliche Toll-Like-Rezeptorproteine, zugehörige Reagenzien und Verfahren
ATE321134T1 (de) Menschlicher fc-gamma-rezeptor iii
CA2345024A1 (en) Modified tgf-.beta. superfamily proteins
DE68929545D1 (de) Pollen Allergene
DE69014474D1 (de) Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
ES2187946T3 (es) Uso de interleucina-15.
ATE132197T1 (de) Monoklonale antikörper
DK0491362T3 (da) Anvendelse af peptidpar med ekstremt høj indbyrdesaffinitet på in vitro - diagnostikområdet
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
DE69315341D1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
ES2142317T3 (es) Polipeptidos de proteinas s y uso de los mismos.
PT524421E (pt) Herpesvirus humano tipo 6 proteina p 100, sequencias de adn correspondentes, preparacao e utilizacao
EP0651800A4 (de) Proteine aus granulabasophilen zellen.